Association between serum adipocyte fatty-acid binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease

Abstract

BackgroundAdipokines, including adipocyte fatty acid-binding protein (A-FABP), have been demonstrated to be involved in the pathogenesis of atherosclerosis. In the present study, we investigated the association of circulating A-FABP level with severity of myocardial perfusion abnormalities analyzed by Tl-201 dipyridamole single-photon emission computed tomography.MethodsA total of 170 patients with coronary artery disease (CAD) from cardiovascular clinics were enrolled in the study. Serum A-FABP levels, echocardiography, and stress myocardial perfusion imaging results were analyzed.ResultsCompared with the patients with mild CAD (summed stress score [SSS] ≤ 8), those with moderate to severe CAD (SSS > 8) had significantly higher A-FABP concentrations. However, the difference was attenuated in the subgroup of patients with heart failure. In the correlation analyses, A-FABP level was correlated with age, body mass index, waist circumference, levels of creatinine, fasting glucose, high-sensitivity C-reactive protein, N-terminal pro-brain natriuretic peptide, adiponectin, and several echocardiographic parameters, including left ventricular ejection fraction. Multivariate logistic regression analysis demonstrated that the A-FABP level was not only associated with higher SSS (odds ratio, 1.30; 95% confidence interval [CI], 1.01–1.69; P = 0.048), but also an independent risk factor for heart failure (odds ratio 2.71, 95% CI, 1.23–5.94; P = 0.013).ConclusionsSerum A-FABP levels not only were associated with myocardial perfusion abnormalities and left ventricular function, but also predicted the presence of heart failure in our patients with CAD.

Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease

“…Liu and coworkers provided the first clinical evidence demonstrating that serum FABP4 concentrations are significantly higher in patients with HF than those in non-HF subjects, and this association was significantly increased with the severity of HF (Liu et al 2013). Interestingly, this association was further confirmed by others (Huang et al 2013, Liu et al 2013. In addition, FABP4 positively correlates with the serum levels of N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP), a well-established and powerful marker of HF risk (Tang et al 2007), and with all echocardiograph parameters, especially LV ejection fraction (LVEF) (Liu et al 2013).…”

“…Moreover, the pharmacological inhibition of FABP4 also significantly protected against atherosclerotic plaque formation in the ApoE-deficient animal model of atherosclerosis, suggesting that the pharmacological inhibition of FABP4 might have beneficial effects against CVD (Furuhashi et al 2007). In humans, FABP4 has been related to subclinical coronary atherosclerosis in type 2 diabetes mellitus subjects (Bagheri et al 2010), and circulating FABP4 levels are also associated with increased carotid intima-media thickness, ischaemic stroke, coronary atherosclerotic burden and the number of stenotic coronary arteries , Rhee et al 2009, Miyoshi et al 2010, Bao et al 2011, Doi et al 2011, Holm et al 2011, Tso et al 2011, Huang et al 2013. Recently, FABP4 has been proposed as a prognostic biomarker in patients with acute coronary syndrome (Reiser et al 2015).…”

“…Specifically, FABP4 levels are associated with LVH as well as systolic and diastolic cardiac dysfunction (Balci et al 2012, Engeli et al 2013, Huang et al 2013, Liu et al 2013, Baessler et al 2014, even in an apparently healthy population (Fuseya et al 2014). A positive correlation between FABP4 and both LV dysfunction and myocardial perfusion abnormalities was found in patients with coronary artery disease (Huang et al 2013). In addition, Engeli and coworkers found a modest but significant independent correlation between FABP4 serum concentrations and the LV mass in overweight and obese women (Engeli et al 2013).…”

Possitive correlation between adipocyte fatty acid-binding protein and epicardial fat in patients with a family history of cardiovascular disesase

“…A-FABP is a promising marker connecting metabolic syndrome, inflammation and atherosclerosis, and recently long term studies 22,23 have been published showing that persons with higher A-FABP levels have poor cardiovascular prognosis. Huang et al 24 published a study where they evaluated the association between serum adipocyte fatty acid-binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary disease. They found an association between the A-FABP level, myocardial perfusion abnormalities and left ventricular function and predicted the presence of heart failure.…”

Pilot Study of A-FABP Levels as a Predictive Factor of SPECT Results in Asymptomatic Relatives of Patients with Cardiovascular Disease

“…The categorical variables (predictive factors) were as follows: gender; age group (10-year groups, range: 40-80 years); CS (as stated above); hypertension; BMI (normal [<25], overweight [25][26][27][28][29][30] or obesity [>30]); diabetes mellitus; and smoking.…”